Form 4: Celldex Therapeutics Executive Receives Stock Option Grant

Celldex Therapeutics reports an executive, Sarah Cavanaugh, received an incentive stock option grant for 95,000 shares.

Summary

• Sarah Cavanaugh, SVP of Corp Affairs & Admin at Celldex Therapeutics, was granted an incentive stock option.
• The option is for 95,000 shares of common stock.
• The exercise price for the option is $34.09 per share.
• The grant date was June 25, 2026.
• Vesting begins on June 25, 2027, with 25% vesting on that date.
• The remaining options vest quarterly over the subsequent 12 quarters.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine stock option grant to an executive without providing new financial performance data or strategic updates.

Positives

• Grant of stock options to a key executive, indicating potential alignment of executive interests with shareholder value.
• The option grant is part of the company's 2021 Omnibus Equity Incentive Plan, suggesting a structured approach to executive compensation.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely reports a stock option grant.

Industry Context

StockSavvy.ai notes that the granting of stock options to senior executives is a common practice in the biotechnology and pharmaceutical sectors, aiming to incentivize long-term performance and retention. This aligns with industry standards for aligning executive compensation with company growth and shareholder value.

Stakeholder Impact

• Shareholders: The grant of options may dilute existing shareholders if exercised, but also aligns executive incentives with potential future stock price appreciation.
• Employees: May signal a positive outlook for the company's future growth, potentially boosting morale.
• Management: Directly benefits from the option grant, contingent on vesting and stock performance.

Next Steps

• Vesting of the stock option grant over the next approximately three years, commencing June 25, 2027.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, Stock Option, Executive Compensation, Incentive Stock Option, Beneficial Ownership, SEC Filing